Improving insulin sensitivity with the peroxisome proliferator-activated receptor (PPAR-)γ agonist pioglitazone was demonstrated to reduce the occurrence of macrovascular events in patients with type 2 diabetes [31]. This evidence concerns the gene INS and type 2 diabetes mellitus.